Cargando…

PRAME Gene Expression in Acute Leukemia and Its Clinical Significance

OBJECTIVE: To investigate the expression of the preferentially expressed antigen of melanoma (PRAME) gene in acute leukemia and its clinical significance. METHODS: The level of expressed PRAME mRNA in bone marrow mononuclear cells from 34 patients with acute leukemia (AL) and in 12 bone marrow sampl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Kai, Wang, Xiao-ming, Fu, Rong, Ruan, Er-bao, Liu, Hui, Shao, Zong-hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643640/ https://www.ncbi.nlm.nih.gov/pubmed/23691459 http://dx.doi.org/10.3969/j.issn.2095-3941.2012.01.013

Ejemplares similares

Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients
por: Kulkarni, Nagaraj V., et al.
Publicado: (2022)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

Intrinsic disorder in PRAME and its role in uveal melanoma
por: Antonietti, Michael, et al.
Publicado: (2023)

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2(Prame) complex
por: Zhang, Wenjuan, et al.
Publicado: (2021)

Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance
por: Yue, Lan-zhu, et al.
Publicado: (2012)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

PRAME Expression in Mucosal Melanoma of the Head and Neck Region
por: Ricci, Costantino, et al.
Publicado: (2023)

Molecular and clinicopathological implications of PRAME expression in adult glioma
por: Le, Minh-Khang, et al.
Publicado: (2023)

Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis
por: Li, Jiaqiang, et al.
Publicado: (2020)

Correction: Intrinsic disorder in PRAME and its role in uveal melanoma
por: Antonietti, Michael, et al.
Publicado: (2023)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma
por: Yang, Lu, et al.
Publicado: (2020)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms’ Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival
por: Khateeb, Engy El, et al.
Publicado: (2014)

Analyses of Molecular and Histopathologic Features and Expression of PRAME by Immunohistochemistry in Mucosal Melanomas
por: Toyama, Aimi, et al.
Publicado: (2019)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience
por: Cazzato, Gerardo, et al.
Publicado: (2022)

PB1789: WT1, HMGA2, EVI1, BAALC AND PRAME MRNA LEVELS IN PATIENTS BLOOD SAMPLES WITH ACUTE LEUKEMIA
por: Stolyar, M., et al.
Publicado: (2022)

PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples
por: Ronchi, Andrea, et al.
Publicado: (2022)

Genetic mechanism for the loss of PRAME in B cell lymphomas
por: Mraz, Marek
Publicado: (2022)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia
por: Wadelin, Frances, et al.
Publicado: (2010)

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020)

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Duplication and positive selection among hominin-specific PRAME genes
por: Birtle, Zoë, et al.
Publicado: (2005)

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
por: Roszik, Jason, et al.
Publicado: (2017)

Genetic mechanism for the loss of PRAME in B cell lymphomas. Reply.
por: Takata, Katsuyoshi, et al.
Publicado: (2022)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Regulation of TRAIL expression by PRAME and EZH2 as potential therapeutic target against solid tumors
por: Mello, Barbara P, et al.
Publicado: (2013)

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
por: Pankov, Dmitry, et al.
Publicado: (2017)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sjbuq3rbjtc32pleeb2n9qcn8l